Freenome's Updated Colorectal Cancer Blood Test Delivers Major Performance Gains, Triggering $70M Abbott Milestone
PCSC is trading near its 52-week low of $10.13 (14% above the low).
Summary
Freenome's updated blood-based colorectal cancer screening test achieved best-in-class detection of precancerous lesions in a pivotal study, triggering a $70M milestone from partner Abbott and reinforcing the value proposition ahead of its SPAC merger with Perceptive Capital Solutions Corp.
Key Events · Product Development and Regulatory · PCSC
-
Updated Test Hits All Endpoints
The updated SimpleScreen CRC test met primary and secondary endpoints, showing 18.2% sensitivity for advanced precancerous lesions (APL) and 41.9% for APL with high-grade dysplasia—the highest reported for a non-invasive blood test in a pivotal study.
-
Significant Performance Improvement
Compared to the first-generation test, APL sensitivity improved from 13.7% to 18.2%, and HGD sensitivity from 30.5% to 41.9%. Modeling projects 9.5% fewer CRC cases and deaths per 100,000 screened.
-
$70M Abbott Milestone Triggered
The positive study outcome triggers a $70 million milestone payment from Abbott, contingent on FDA approval of the next-generation test and technology transfer, providing non-dilutive capital to the combined company.
-
Regulatory Path Forward
Freenome intends to submit a supplemental PMA to the FDA for the updated test. The first-generation test PMA is under review with a decision expected mid-2026.
Analysis · PCSC · Industrial Applications And Services
A significant leap in detecting advanced precancerous lesions—the key to preventing colorectal cancer—has been delivered by Freenome's updated SimpleScreen CRC blood test. Sensitivity for advanced precancerous lesions jumped to 18.2% from 13.7%, and for high-grade dysplasia to 41.9% from 30.5%, the highest reported for any non-invasive blood test in a pivotal study. Modeling translates this into 9.5% fewer cancer cases and deaths per 100,000 screened. These results also unlock a $70 million milestone payment from Abbott upon FDA approval of the next-generation test, strengthening the combined company's cash position ahead of the SPAC merger close. With the merger vote imminent and the S-4 already effective, this data de-risks the commercial thesis and validates the platform's competitive edge in the massive CRC screening market.
At the time of this filing, PCSC was trading at $11.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $117.6M. The 52-week trading range was $10.13 to $14.47. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.